Labeled Ticagrelor , the first reversible oral P2Y12 receptor antagonist, provides faster, greater, and more consistent ADP-receptor inhibition than Clopidogrel. Used in the treatment of acute coronary syndromes (ACS)
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.